DSpace Repository

Tafenoquine for the treatment of Plasmodium vivax malaria

Show simple item record

dc.contributor.author Llanos Cuentas, Elmer Alejandro
dc.contributor.author Manrrique, P.
dc.contributor.author Rosas-Aguirre, A.
dc.contributor.author Herrera, S.
dc.contributor.author Hsiang, M.S.
dc.date.accessioned 2022-06-25T20:36:42Z
dc.date.available 2022-06-25T20:36:42Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/11869
dc.description.abstract Introduction: Plasmodium vivax malaria causes significant disease burden worldwide, especially in Latin America, Southeast Asia, and Oceania. P. vivax is characterized by the production of liver hypnozoites that cause clinical relapses upon periodic activation. Primaquine, an 8-aminoquinoline drug, has been the standard of care for decades to treat liver-stage P. vivax malaria; however, it requires long treatment regimens (one to two weeks) that lead to poor adherence and thus clinical relapses. Tafenoquine (TFQ), a newly available and efficacious single-dose 8-aminoquinoline, aims to address this challenge. Safe administration is possible when paired with the use of glucose-6-phosphate dehydrogenase (G6PD) diagnostics to prevent 8-aminoquinoline-induced hemolysis in patients with underlying G6PD deficiency (G6PDd). Areas covered: In this review, the authors present the recent literature regarding the pharmacology, efficacy, safety, and tolerability of TFQ and highlight regional differences in these areas. The authors also discuss the potential for TFQ, complemented with primaquine PQ and effective screening for G6PDd, to improve P. vivax clinical management and facilitate targeted mass drug administration in communities to decrease transmission. Expert opinion: Clinical studies show therapeutic efficacy of TFQ as well as a good performance in terms of safety and tolerability. Additional research regarding the effectiveness and safety TFQ in malaria elimination strategies, such as targeted or mass drug administration, are needed. en_US
dc.language.iso eng
dc.publisher Taylor and Francis
dc.relation.ispartofseries Expert Opinion on Pharmacotherapy
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Malaria vivax en_US
dc.subject tafenoquine en_US
dc.subject primaquine en_US
dc.subject radical cure en_US
dc.subject safety en_US
dc.title Tafenoquine for the treatment of Plasmodium vivax malaria en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1080/14656566.2022.2058394
dc.relation.issn 1744-7666


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics